GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NextCure Inc.
NextCure is an oncology company focused on immuno-oncology. Its stock price represents a venture bet on its scientific platform. The stock price reflects high volatility and reliance on news about the clinical trials of its drug candidates.
Share prices of companies in the market segment - Oncology immuno-therapy
NextCure is an oncology company developing next-generation immunotherapeutics that target novel tumor microenvironments. We've categorized it as "Immuno-Oncology." The chart below shows how investors value companies pursuing breakthroughs in this field.
Broad Market Index - GURU.Markets
NextCure is an oncology company developing next-generation immunotherapy drugs. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how NextCure shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
NXTC - Daily change in the company's share price NextCure Inc.
NextCure, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its immuno-oncology drugs.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
NextCure, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with NXTC's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
NextCure is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NextCure Inc.
NextCure, Inc.'s year-over-year performance is a story of next-generation immuno-oncology drug development. Its 12-month market cap is entirely dependent on early clinical trial data. Positive results on its unique targets could validate the potential of its scientific platform and attract major partners.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
NextCure, Inc. is a clinical-stage biotech company developing immunotherapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NextCure is an immuno-oncology company whose stock is a bet on a new generation of cancer drugs. Its performance is completely disconnected from the market and is determined by news of the clinical successes or failures of its drugs. It's a high-risk play, where scientific data can change everything overnight.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NextCure Inc.
NextCure is a clinical-stage immuno-oncology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its leading programs, presented at conferences, is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
NextCure is a biotech company discovering and developing a new generation of immuno-oncology drugs that target previously unknown targets in the tumor microenvironment. The graph below shows the overall dynamics of the immunotherapy sector, reflecting the ongoing scientific search for new ways to fight cancer.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where news about clinical trials trumps broader market trends. The chart below shows the pulse of the broader market. Does NextCure move in sync with it, or are breakthroughs in its R&D pipeline creating a completely independent story for the stock?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NextCure Inc.
NextCure is an oncology company developing next-generation immunotherapies. Its weekly stock price, typical for early-stage biotech companies, is entirely dependent on clinical trial data. The chart reflects hopes for a new breakthrough in the fight against cancer.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
NextCure is a biotech company in the immuno-oncology field, where news is king. This chart is a great tool for understanding whether sharp weekly stock fluctuations are the result of a breakthrough in the company's research or reflect general optimism or pessimism in the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NextCure is an oncology biotech company. Its success depends on scientific breakthroughs, not unemployment. This chart clearly shows how often the company's shares move against the broader market in response to research data releases. How immune is it to overall market volatility?
Market capitalization of the company, segment and market as a whole
NXTC - Market capitalization of the company NextCure Inc.
The NextCure, Inc. chart is a visual representation of scientific research in immuno-oncology. Its market cap reflects investors' faith in new approaches to cancer treatment. Its volatile curve is a direct response to preclinical and early clinical trial data, where both risks and potential rewards are high.
NXTC - Share of the company's market capitalization NextCure Inc. within the market segment - Oncology immuno-therapy
NextCure is a biopharmaceutical company developing next-generation immuno-oncology drugs. In this cutting-edge segment, its market capitalization reflects the potential of its scientific platform. The company's market capitalization reflects a bet that its approaches to stimulating the immune system to fight cancer will be more effective than existing methods.
Market capitalization of the market segment - Oncology immuno-therapy
NextCure is an immuno-oncology company. How big is this arena? The chart below shows the pulse of the entire sector. Its high volatility reflects both the enormous hopes for new cancer treatments and the high risks associated with early-stage clinical development.
Market capitalization of all companies included in a broad market index - GURU.Markets
The NextCure chart is a visualization of the next-generation research in immuno-oncology. This biotech company's market cap is a bet on its scientific platform and drug candidates. Its volatile dynamics reflect early-stage research, where any result can radically change prospects.
Book value capitalization of the company, segment and market as a whole
NXTC - Book value capitalization of the company NextCure Inc.
For NextCure, an immuno-oncology company, book value is its tangible assets: cutting-edge laboratories, its proprietary FIND-IO™ target discovery platform, and financial reserves for R&D. The chart below shows how the company built its physical and financial foundation for developing new cancer drugs.
NXTC - Share of the company's book capitalization NextCure Inc. within the market segment - Oncology immuno-therapy
NextCure, Inc. is an immuno-oncology company whose tangible assets are cutting-edge research laboratories where new generations of cancer drugs are discovered and developed. These R&D centers are its physical base for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Oncology immuno-therapy
NextCure is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. NextCure focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
NextCure's assets are not factories, but cutting-edge laboratories and the FIND-IO® scientific platform for discovering new targets in immuno-oncology. The book value reflects the material base for this fundamental research, which could lead to the creation of next-generation drugs. The chart illustrates its scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NextCure Inc.
NextCure is a biotech company developing next-generation immunotherapies for cancer treatment. Its balance sheet represents cash flow for research. Its market capitalization is the valuation of its scientific platform, FIND-IO. The chart shows how the market views its innovative approach and the potential of its early-stage drug candidates.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
NextCure is a biotech company developing next-generation immunotherapies for cancer treatment. Its market value is based on the potential of its scientific platform. The chart shows the premium investors place on its innovative approach to oncology compared to its current assets.
Market to book capitalization ratio for the market as a whole
NextCure is an immuno-oncology company. Its market capitalization reflects investors' bets on the success of its scientific platform and future cancer treatments. This chart clearly demonstrates how the valuation of biotech companies is disconnected from their book value and depends solely on faith in a future scientific breakthrough.
Debts of the company, segment and market as a whole
NXTC - Company debts NextCure Inc.
NextCure is a biotech company developing next-generation immuno-oncology drugs. While in clinical trials, the company relies entirely on external funding. This chart shows how NextCure uses raised capital to support its innovative, yet highly expensive, research programs in one of the most advanced fields of medicine.
Market segment debts - Oncology immuno-therapy
NextCure is a clinical-stage biotech company developing next-generation immunotherapies for cancer treatment. Its scientific platform requires significant and ongoing investment. This chart shows its financial health, which is entirely dependent on its ability to raise equity capital to fund its cutting-edge research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NextCure Inc.
NextCure is a biotech company developing immuno-oncology drugs. This chart shows its financial structure. For a clinical-stage company operating in one of the most competitive areas of biopharma, debt is a significant risk. Success depends on breakthrough scientific results, not the ability to service debt.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
NextCure is a biotech company developing next-generation immuno-oncology drugs. Its goal is to find new targets to fight cancer. This chart shows the overall debt load in the sector, which helps us understand how NextCure finances its cutting-edge, yet highly risky and expensive, research.
Debt to book value of all companies in the market
NextCure, Inc. is a biotech company developing a new generation of immuno-oncology therapeutics. Being in early clinical development, it relies entirely on equity capital. This chart highlights the chasm between the investor-funded world of science and the established business world that relies on debt markets.
P/E of the company, segment and market as a whole
P/E - NextCure Inc.
For NextCure, a clinical-stage immuno-oncology company, P/E is not a meaningful metric. It has no products or revenues. Its valuation on this chart is arbitrary. The company's true value is determined by investors' faith in the potential of its scientific platform to create a new generation of cancer drugs.
P/E of the market segment - Oncology immuno-therapy
NextCure is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology drugs for the treatment of cancer and other diseases. This chart shows the average valuation for the sector, helping to understand how the market views NextCure's scientific platform and pipeline.
P/E of the market as a whole
NextCure is a biotech company developing next-generation immuno-oncology drugs. Its valuation is a pure bet on the success of its scientific platform. It has no connection to the general economic cycles depicted by this chart. NextCure's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NextCure Inc.
NextCure is a clinical-stage biotech developing next-generation immuno-oncology therapeutics. This chart reflects investor expectations for its FIND-IO research platform. The valuation is based on the long-term potential to discover new targets for cancer immunotherapy, not on current financial performance.
%20P%2FE%20NextCure%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NextCure-Inc.&v=1772649644574 "Chart of the company's future (projected) P/E NextCure Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
NextCure is a biopharmaceutical company focused on immuno-oncology. Its valuation relative to other biotechs in this hot field reflects investors' views on its unique scientific platform for discovering new drug targets. This is a bet that its approach will lead to the creation of a new generation of cancer treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772649644656 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
NextCure is a biopharmaceutical company developing next-generation immuno-oncology drugs. Its value is almost entirely determined by expectations for clinical trials. This chart shows investors' overall risk appetite. For early-stage biotechs like NextCure, market optimism is critical to raising the capital needed to continue development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772649644840 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NextCure Inc.
NextCure is a clinical-stage biotechnology company focused on immuno-oncology. The financial performance shown here reflects its expenditures on the discovery and development of next-generation cancer drugs. Future results depend on the success of its innovative approaches in clinical trials.
Profit of companies in the market segment - Oncology immuno-therapy
NextCure is an oncology company developing next-generation immunotherapeutic drugs. This chart reflects the financial health of the immuno-oncology sector. It shows whether this cutting-edge approach to cancer treatment remains commercially attractive, or whether the market is saturated and development costs are too high.
Overall market profit
NextCure is a biopharmaceutical company focused on immuno-oncology. It strives to find new ways to fight cancer. Its value is based on the potential of its scientific developments. This chart, showing economic cycles, is relevant for NXTC only from an investment climate perspective, but the fundamental decisions are made in the lab and during clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NextCure Inc.
NextCure is a biotech company developing a new generation of immuno-oncology therapeutics. Its future revenue projections are a long-term bet on the success of its scientific platform. This chart reflects analysts' belief that its innovative approaches to cancer treatment will ultimately lead to commercially successful drugs.
%20profit%20of%20the%20company%20NextCure%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NextCure-Inc.&v=1772649645037 "Graph of future (projected) profit of the company NextCure Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
NextCure is a biotech company developing next-generation immuno-oncology drugs. Their goal is to find new targets to attack cancer cells that are unresponsive to existing treatments. This chart shows forecasts for the immunotherapy segment, illustrating the hopes placed on scientific breakthroughs to expand the arsenal in the fight against cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772649645083 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
The overall market profitability outlook influences investor willingness to fund biotech. NextCure, which focuses on immuno-oncology, requires significant funding for its development. A favorable economic environment facilitates capital inflows, while a recession could freeze funding for promising research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772649645152 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NextCure Inc.
NextCure is an immuno-oncology company. This chart, despite the almost complete absence of sales, illustrates the market's valuation of its scientific platform. Investors are buying not current revenue, but the potential of its future cancer treatments.
P/S market segment - Oncology immuno-therapy
NextCure is a biopharmaceutical company focused on the discovery and development of innovative immuno-oncology therapeutics. This chart shows the average valuation in the immunotherapy sector. It reflects investor confidence in the potential of new cancer treatment approaches and provides an insight into how the market perceives NextCure's scientific platform.
P/S of the market as a whole
NextCure, Inc. is a biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapeutics. The company's valuation is based on the potential of its FIND-IO scientific platform. This chart serves as a contrast, showing how the market values companies with real revenues compared to those at the forefront of science.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NextCure Inc.
NextCure is a biotech company developing next-generation immuno-oncology drugs. Its valuation is based on the potential of its FIND-IO scientific platform. This chart reflects investors' confidence that its cancer treatment approaches will be successful in the clinic, leading to the development of sought-after drugs and high revenues.
%20P%2FS%20NextCure%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NextCure-Inc.&v=1772649645222 "The graph of the company's future (projected) P/S NextCure Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
NextCure is a biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology drugs. It is exploring new targets to stimulate the immune system in the fight against cancer. This chart reflects investor expectations for its scientific platform and the potential of future drugs compared to other immuno-oncology companies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772649645236 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
This chart shows general expectations for the immuno-oncology market. For NextCure, a biotech company developing a new generation of anti-cancer drugs, this is an indicator of the investment climate. Market optimism allows it to attract capital for research into innovative targets that could help the immune system fight tumors.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772649645270 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NextCure Inc.
NextCure is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immuno-oncology therapeutics. This chart reflects revenue from collaborations with other pharmaceutical companies. Future revenue growth will depend on the success of clinical trials and the commercialization of antibodies targeting novel immune checkpoints.
Sales of companies in the market segment - Oncology immuno-therapy
NextCure is a biotech company developing a new generation of immuno-oncology drugs. This chart shows the growth of the cancer immunotherapy market. NextCure is seeking new targets to attack tumors that are resistant to existing treatments, placing it at the forefront of one of the most promising areas in modern oncology.
Overall market sales
NextCure, Inc. is a biopharmaceutical company developing next-generation immuno-oncology drugs. Its value depends on the success of its clinical programs. The overall economic situation, reflected in this chart, influences investor sentiment and their willingness to invest in high-risk but promising biotechnologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NextCure Inc.
NextCure is a biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology drugs. Its goal is to find new targets to fight cancer. Future revenues are dependent on the success of its early clinical programs. This chart reflects analysts' assessment of the scientific potential of NextCure's platform and its ability to create breakthrough drugs.
%20sales%20of%20the%20company%20NextCure%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NextCure-Inc.&v=1772649645387 "Schedule of future (projected) sales of the company NextCure Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
NextCure is a biotech company developing next-generation immuno-oncology drugs. This chart reflects expectations for the entire cancer immunotherapy sector. It shows how much investors and analysts believe in the potential of new approaches to cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772649645402 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
NextCure, Inc. is a biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapeutics. Its value is determined by the potential of its scientific platform. The overall economic environment, illustrated in this chart, influences the flow of venture capital into biotech, which is essential for funding cutting-edge and risky research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772649645443 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NextCure Inc.
NextCure is a biotech company developing a new generation of immuno-oncology drugs. The chart reflects the financial picture during the intensive research phase. Negative values represent strategic investments in the scientific platform, which is designed to create breakthrough cancer treatments and ensure high profits in the future.
Market segment marginality - Oncology immuno-therapy
NextCure is a biopharmaceutical company developing next-generation immuno-oncology therapies. For a company in clinical development, this chart is an important benchmark. It reflects the average profitability in the sector, demonstrating the potential financial return from the successful commercialization of their innovative cancer treatments.
Market marginality as a whole
NextCure is a biopharmaceutical company developing next-generation immuno-oncology drugs. This total market profitability figure is not directly relevant to the company. Its future success depends on breakthrough scientific discoveries and clinical trial results. The company's potential lies in its ability to create fundamentally new cancer treatments.
Employees in the company, segment and market as a whole
Number of employees in the company NextCure Inc.
NextCure is a biotech company working in the field of immuno-oncology. This graph shows a small but highly specialized team of scientists. Their number reflects the company's focus on the early stages of cancer drug discovery and development, where science trumps scale.
Share of the company's employees NextCure Inc. within the market segment - Oncology immuno-therapy
NextCure is at the forefront of immuno-oncology, developing a new generation of cancer drugs. This chart shows the percentage of leading immunologists, oncologists, and biologists in this cutting-edge field that the company attracts. It reflects its concentration of scientific talent needed to achieve breakthroughs in cancer treatment.
Number of employees in the market segment - Oncology immuno-therapy
NextCure is a biopharmaceutical company developing next-generation immuno-oncology drugs. Its goal is to find treatments for patients who have not responded to existing therapies. This graph illustrates how science is delving deeper into the workings of the immune system, creating a demand for immunologists and oncologists working on the front lines of the fight against cancer.
Number of employees in the market as a whole
NextCure is an immuno-oncology company at the forefront of the fight against cancer. Its activities create a demand for unique biotech specialists. This graph illustrates the overall labor market, but it is companies like NextCure that shape its most valuable and knowledge-intensive segment, ensuring the country's technological leadership.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NextCure Inc. (NXTC)
NextCure is a biotech company specializing in immuno-oncology. This chart is a classic example of intellectual capital valuation. The company has no commercial products; its value is based entirely on expectations for its scientific platform (FIND-IO). The chart shows how highly the market values this scientific potential and development pipeline per scientist.
%20of%20the%20company%20NextCure%20Inc.%20(NXTC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NextCure-Inc.-NXTC&v=1772649646007 "Chart of market capitalization per employee (in thousands of dollars) of the company NextCure Inc. (NXTC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
NextCure is a biotech company working in the field of immuno-oncology. Its market capitalization is essentially a measure of investor expectations for future drugs developed by its team of scientists. The chart shows how highly the market values the intellectual contribution of each NextCure employee compared to other companies searching for cancer cures.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772649646120 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
NextCure, Inc. is a biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapeutics. This chart represents the overall market productivity metric, highlighting the enormous value the market places on scientific innovation.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772649646197 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NextCure Inc. (NXTC)
NextCure is a clinical-stage biotech company focused on immuno-oncology. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist to conduct R&D and discover new cancer treatments.
%20Chart%20NextCure%20Inc.%20(NXTC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NextCure-Inc.-NXTC&v=1772649646250 "Company Profit Per Employee (in thousands of dollars) Chart NextCure Inc. (NXTC)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
NextCure is a biopharmaceutical company developing next-generation immunotherapeutic drugs for cancer treatment. Its core assets are its scientific development and research team. This chart demonstrates how investments in intellectual capital and breakthrough technologies drive the company's potential value per employee, which is typical for innovative companies in clinical trials.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772649646299 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
NextCure (NXTC) is a clinical-stage biotech focused on the discovery and development of next-generation immuno-oncology therapeutics. It's a pure R&D operation. This chart shows the average profitability per employee across the market. For NXTC (which is currently losing money), this is a benchmark: in biotech, a small team of scientists can create a product that will significantly exceed this average in the future.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772649646319 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NextCure Inc. (NXTC)
NextCure is a clinical-stage biopharmaceutical company focused on immuno-oncology. This chart is a glimpse into the future. For a company at the forefront of science, it reflects the potential revenue its innovative cancer treatments could generate if they prove successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NextCure-Inc.-NXTC&v=1772649646377 "Sales chart per company employee NextCure Inc. (NXTC)")
Sales per employee in the market segment - Oncology immuno-therapy
NextCure is a clinical-stage biotech company focused on immuno-oncology. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of NextCure's staff within the industry.
Sales per employee for the market as a whole
NextCure is a clinical-stage biotechnology company specializing in immuno-oncology. The company has no approved products and, consequently, no commercial revenue. This metric is currently irrelevant. The R&D team is fully focused on successfully completing clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company NextCure Inc. (NXTC)
NextCure is a clinical-stage biotech company exploring new targets for cancer immunotherapy. This is an extremely risky field where most drugs fail. This chart shows the number of "bears" betting that their scientific approach will be flawed, the trials will fail, and the company will burn through its capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NextCure-Inc.-NXTC&v=1772649646592 "Short Shares Chart for the Company NextCure Inc. (NXTC)")
Shares shorted by market segment - Oncology immuno-therapy
NextCure, Inc. is a biotech company focused on immuno-oncology. They are exploring new targets (beyond PD-1) to stimulate the immune system to fight cancer. This chart reflects the total short position in the immuno-oncology sector. High values indicate general investor skepticism about the success of clinical trials of new, unproven immune targets.
Shares shorted by the overall market
NextCure is a biotech company working in immuno-oncology. It's at the cutting edge of science. This chart illustrates the overall market pessimism. When investors panic, they're unwilling to fund complex scientific concepts. They see R&D costs and a lack of profitability, and they sell their shares, fearing they'll run out of cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NextCure Inc. (NXTC)
This chart for NextCure is an indicator of confidence in new immuno-oncology targets. The company is exploring new avenues to fight cancer (beyond PD-1). "Overbought" (above 70) occurs due to early data showing a "signal" in patients. However, disappointing results as trials progress and the high level of competition in this field lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NextCure-Inc.-NXTC&v=1772649646851 "RSI 14 indicator chart for the company's stock NextCure Inc. (NXTC)")
RSI 14 Market Segment - Oncology immuno-therapy
NextCure (NXTC) is a biotech company focused on cancer (immuno-oncology). The oncology immuno-therapy (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether NXTC's growth is due to their R&D or simply the entire biotech sector being overheated.
RSI 14 for the overall market
NextCure (NXTC) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NXTC (NextCure Inc.)
NextCure (NXTC) is an immuno-oncology company developing "next-generation" drugs targeting new immune pathways to fight cancer. This chart shows the average price target. It reflects analysts' speculative valuations of its scientific platform and early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NXTC-NextCure-Inc.&v=1772649646997 "A chart showing analyst consensus forecasts for the expected stock price. NXTC (NextCure Inc.)")
The difference between the consensus estimate and the actual stock price NXTC (NextCure Inc.)
NextCure is an immuno-oncology company developing antibodies (the FIND-IO platform) for patients who do not respond to existing immunotherapy (PD-1). This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and the forecast, reflecting their confidence in this cutting-edge R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NXTC-NextCure-Inc.&v=1772649647011 "A chart showing the difference between the consensus forecast and the actual stock price. NXTC (NextCure Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
NextCure is a biotech R&D platform. The company uses its "search engine" (FIND-IO) to discover entirely new targets for cancer immunotherapy. This chart reflects analysts' overall expectations for the entire immunotherapy sector. It shows whether experts believe new R&D approaches are successful or whether they consider the sector overheated.
Analysts' consensus forecast for the overall market share price
NextCure is a biotech company developing next-generation immunotherapies (targeting non-PD1 targets) for cancer treatment. This chart shows the overall market appetite. For NextCure, a high-risk clinical-stage company, overall market optimism (as shown by the rising chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NextCure Inc.
NextCure is a biotech R&D company working in immuno-oncology. They focus on new, previously unknown checkpoints (signals) that cancer uses to hide from the immune system. This chart is a pure indicator of their belief in R&D. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Oncology immuno-therapy
NextCure (NXTC) is an immuno-oncology company that uses its platform (FIND-IO) to discover new, previously unknown targets on immune cells to develop cancer drugs. The chart shows the segment average, helping investors assess how this exploratory R&D strategy compares to the sector average.
The AKIM Index for the overall market
NextCure is a biopharmaceutical company developing next-generation immunomedicine (immuno-oncology) targeting unique molecular pathways. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific story fits in with the overall economic trends affecting biotech.
